Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Barrientos, Jacqueline C. (Zucker School of Medicine at Hofstra/Northwell)
O'Brien, Susan (University of California Irvine)
Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Kay, Neil E. (Mayo Clinic)
Reddy, Nishitha M. (Vanderbilt-Ingram Cancer Center)
Coutre, Steven E (Stanford University School of Medicine)
Tam, Constantine (Peter MacCallum Cancer Centre and St Vincent's Hospital)
Mulligan, Stephen (Royal North Shore Hospital)
Jaeger, Ulrich (Medical University of Vienna)
Devereux, Stephen (King's College Hospital NHS Foundation Trust)
Pocock, Christopher (East Kent Hospitals University)
Robak, Tadeusz (Medical University of Lodz)
Schuster, Stephen J. (Perelman Center for Advanced Medicine)
Schuh, Anna (University of Oxford)
Gill, Devinder (Princess Alexandra Hospital)
Bloor, Adrian (The Christie Clinic)
Dearden, Claire (The Royal Marsden Hospital)
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau)
Cull, Gavin (Sir Charles Gardiner Hospital)
Hamblin, Mike (Colchester Hospital)
Jones, Jeffrey A. (The Ohio State University Comprehensive Cancer Center)
Eckert, Karl (Pharmacyclics LLC. an AbbVie Company)
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company)
Suzuki, Samuel (Pharmacyclics LLC. an AbbVie Company)
Hsu, Emily (Pharmacyclics LLC. an AbbVie Company)
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company)
Byrd, John C. (The Ohio State University Comprehensive Cancer Center)
Hillmen, Peter (The Leeds Teaching Hospitals. St. James University Hospital)
Universitat Autònoma de Barcelona

Date:	2018
Abstract:	In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. These results suggest that ibrutinib can improve quality of life while prolonging survival. Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Measures of well-being were assessed in RESONATE, where previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day (n = 195) or ofatumumab (n = 196) for up to 24 weeks. Endpoints included hematologic function, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), disease-related symptoms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (EORTC QLQ-C30), and medical resource utilization. With up to 24 months' follow-up (median, 16. 4 months), 79% of cytopenic patients showed sustained hematologic improvement (82% with improved platelet count, 69% with improved hemoglobin) on ibrutinib versus 43% on ofatumumab (P <. 0001). Higher rates of clinically meaningful improvement were demonstrated with ibrutinib versus ofatumumab for FACIT-F and EORTC global health. Greater improvement was observed in disease-related weight loss, fatigue, night sweats, and abdominal discomfort with ibrutinib versus ofatumumab. Hospitalizations in the first 30 days occurred less frequently with ibrutinib than ofatumumab (0. 087 vs. 0. 184 events/patient; P =. 0198). New-onset diarrhea was infrequent with ibrutinib after the first 6 months (47% at ≤6 months vs. 5% at 12-18 months). With ibrutinib, grade ≥ 3 hypertension occurred in 6%, grade ≥ 3 atrial fibrillation in 4%, major hemorrhage in 2%, and tumor lysis syndrome in 1% of patients. Conclusion: Ibrutinib led to significant improvements in hematologic function and disease symptomatology versus ofatumumab, and can restore quality of life while prolonging survival in relapsed/refractory CLL/SLL.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Bruton's tyrosine kinase ; Disease-related symptoms ; Fatigue ; Quality of life ; Relapsed/refractory CLL/SLL
Published in:	Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 12 (december 2018) , p. 803-813.e7, ISSN 2152-2669

DOI: 10.1016/j.clml.2018.08.007
PMID: 30249389

19 p, 600.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles